To review our experience with MRI-guided in-bore prostate biopsy (MRGB) and present a review of the literature on MRGB.
A retrospective review of patients presenting for MRGB between 2013 and 2018. Diagnostic and biopsy MRI scans were reviewed to collect data on scan dates, procedure times, characteristics of MRI targets (PI-RADS™ score, target size, ADC value and location). A review of the literature on MRGB for the period 2013–2018 was performed.
607 targets in 554 men were biopsied. Overall and significant cancer detection rate were 80% and 55% at a patient level, and 76 and 59% at the target level, respectively. Prostate cancer (CaP) detection in men with prior negative biopsy was 60% while 50% of men on active surveillance were upgraded to clinically significant disease (CSD). Lesion location did not predict for presence of CaP or CSD. PI-RADS™ score, age and PSAD were predictors of CSD at biopsy on multivariate analysis. Literature review identified 23 reports reporting on MRGB cohorts (~ 4000 patients). Overall cancer detection ranged from 23 to 74% and CSD in 63% overall. CaP detection in PI-RADS™ 3 targets was substantially lower in our series and the literature than for PI-RADS™ 4–5 targets.
MRGB in PI-RADS™ 3–5 targets yields high rates of cancer diagnosis. High detection rates are also seen in men with prior negative biopsy and AS cohorts. PI-RADS™ score, age and PSAD can reliably predict CSD detection. The number of published series is small and the role of MRGB in PI-RADS™ 3 targets needs further study.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Apparent diffusion co-efficient
Cancer core length
Clinically significant disease
Digital imaging and communications in medicine
International Society of Urological Pathology
Multiparametric magnetic resonance imaging
In-bore MRI-guided biopsy
Magnetic resonance imaging
Prostate Imaging-Reporting and Data System
Transrectal ultrasound (guided)
Weinreb JC et al (2016) PI-RADS prostate imaging-reporting and data system: 2015, version 2. Eur Urol 69(1):16–40
Fütterer JJ et al (2015) Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68(6):1045–1053
Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ (2018) Is MRI-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis. BJU Int. https://doi.org/10.1111/bju.14358
Overduin CG, Fütterer JJ, Barentsz JO (2013) MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Curr Urol Rep 14(3):209–213
Bjurlin MA et al. MRI of the Prostate, Standard Operating Procedure (SOP). American Urological Association. https://www.auanet.org/guidelines/mri-of-the-prostate-sop. Accessed 24 Sept 2018
Prostate cancer: diagnosis and management | Guidance and guidelines | NICE. [Online]. https://www.nice.org.uk/guidance/cg175/chapter/1-recommendations. Accessed 02 Jun 2018
Christidis D, McGrath S, Leaney B, O’Sullivan R, Lawrentschuk N (2018) Interpreting prostate multiparametric magnetic resonance imaging: urologists’ guide including prostate imaging reporting and data system. Urology 111:136–138
Pokorny MR et al (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66(1):22–29
Schouten MG et al (2017) Why and where do we miss significant prostate cancer with multi-parametric magnetic resonance imaging followed by magnetic resonance-guided and transrectal ultrasound-guided biopsy in biopsy-naïve men? Eur Urol 71(6):896–903
Yaxley AJ, Yaxley JW, Thangasamy IA, Ballard E, Pokorny MR (2017) Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3–5 MRI lesions. BJU Int 120(Suppl 3):43–50
Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee (2005) “The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma”. Am J Surg Pathol 29(9):1228–1242
Epstein JI et al (2016) “The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system”. Am J Surg Pathol 40(2):244–252
Venderink W et al (2017) Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer. Eur Urol 73(3):353–360
Elkjær MC, Andersen MH, Høyer S, Pedersen BG, Borre M (2018) Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment. Acta Radiol Stockh Swed 59(5):619–626
Addicott B, Foster BR, Johnson C, Fung A, Amling CL, Coakley FV (2017) Direct magnetic resonance imaging-guided biopsy of the prostate: lessons learned in establishing a regional referral center. Transl Androl Urol 6(3):395–405
Wang Y et al (2018) Optimal biopsy strategy for prostate cancer detection by performing a Bayesian network meta-analysis of randomized controlled trials. J Cancer 9(13):2237–2248
Murphy IG, NiMhurchu E, Gibney RG, McMahon CJ (2017) MRI-directed cognitive fusion-guided biopsy of the anterior prostate tumors. Diagn Interv Radiol 23(2):87–93
Ahmed HU et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet Lond Engl 389(10071):815–822
Kasivisvanathan V et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. New Engl J Med 378(19):1767–1777
Jyoti R, Jina NH, Haxhimolla HZ (2017) In-gantry MRI guided prostate biopsy diagnosis of prostatitis and its relationship with PIRADS V. 2 based score. J Med Imaging Radiat Oncol 61(2):212–215
Venderink W, Govers TM, de Rooij M, Fütterer JJ, Sedelaar JPM (2017) Cost-effectiveness comparison of imaging-guided prostate biopsy techniques: systematic transrectal ultrasound, direct in-bore MRI, and image fusion. AJR Am J Roentgenol 208(5):1058–1063
de Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JPC (2014) Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol 66(3):430–436
Pahwa S, Schiltz NK, Ponsky LE, Lu Z, Griswold MA, Gulani V (2017) Cost-effectiveness of MR imaging-guided strategies for detection of prostate cancer in biopsy-naive men. Radiology 285(1):157–166
Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J (2017) The use of biomarkers in prostate cancer screening and treatment. Rev Urol 19(4):221–234
Ting F et al (2016) Assessment of the performance of magnetic resonance imaging/ultrasound fusion guided prostate biopsy against a combined targeted plus systematic biopsy approach using 24-core transperineal template saturation mapping prostate biopsy. Prostate Cancer. https://doi.org/10.1155/2016/3794738
Niu X, Li J, Das SK, Xiong Y, Yang C, Peng T (2017) Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone. BMC Med Imaging 17(1):11
Wegelin O et al (2017) Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. is there a preferred technique? Eur Urol 71(4):517–531
Sathianathen NJ, Christidis D, Konety BR, Lawrentschuk NL (2018) Magnetic resonance imaging cognitive fusion biopsy-is near enough good enough? BJU Int 121(3):324–326
Porpiglia F et al (2018) Comparing image-guided targeted biopsies to radical prostatectomy specimens for accurate characterization of the index tumor in prostate cancer. Anticancer Res 38(5):3043–3047
Radtke JP et al (2016) Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol 70(5):846–853
Borkowetz A et al (2016) Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography-fusion biopsy. BJU Int 118(2):213–220
Baco E et al (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794
Borghesi M et al (2017) Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 71(3):353–365
Friedl A et al (2018) In-bore 3.0-T magnetic resonance imaging-guided transrectal targeted prostate biopsy in a repeat biopsy population: diagnostic performance, complications, and learning curve. Urology 114:139–146
Durmuş T, Reichelt U, Huppertz A, Hamm B, Beyersdorff D, Franiel T (2013) MRI-guided biopsy of the prostate: correlation between the cancer detection rate and the number of previous negative TRUS biopsies. Diagn Interv Radiol 19(5):411–417
Mouraviev V et al (2013) The feasibility of multiparametric magnetic resonance imaging for targeted biopsy using novel navigation systems to detect early stage prostate cancer: the preliminary experience. J Endourol 27(7):820–825
Garmer M, Busch M, Mateiescu S, Fahlbusch DE, Wagener B, Grönemeyer DHW (2015) Accuracy of MRI-targeted in-bore prostate biopsy according to the Gleason score with postprostatectomy histopathologic control—a targeted biopsy-only strategy with limited number of cores. Acad Radiol 22(11):1409–1418
Liddell H, Jyoti R, Haxhimolla HZ (2015) mp-MRI Prostate characterised PIRADS 3 Lesions are associated with a low risk of clinically significant prostate cancer-A retrospective review of 92 biopsied PIRADS 3 lesions. Curr Urol 8(2):96–100
Felker ER et al (2016) In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol 41(5):954–962
Kasel-Seibert M et al (2016) Assessment of PI-RADS v2 for the detection of prostate cancer. Eur J Radiol 85(4):726–731
Schimmöller L et al (2016) Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required? Eur Radiol 26(11):3858–3864
Tewes S et al (2016) Standardized reporting of prostate MRI: comparison of the prostate imaging reporting and data system (PI-RADS) version 1 and version 2. PLoS One 11(9):e0162879
Osses DF, van Asten JJ, Kieft GJ, Tijsterman JD (2017) Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score. World J Urol 35(2):207–212
Schiavina R et al (2017) ‘In-bore’ MRI-guided prostate biopsy using an endorectal nonmagnetic device: a prospective study of 70 consecutive patients. Clin Genitourin Cancer 15(3):417–427
Tan N et al (2017) In-Bore 3-T MR-guided transrectal targeted prostate biopsy: prostate imaging reporting and data system version 2-based diagnostic performance for detection of prostate cancer. Radiology 283(1):130–139
Bastian-Jordan M (2018) Magnetic resonance imaging of the prostate and targeted biopsy, Comparison of PIRADS and Gleason grading. J Med Imaging Radiat Oncol 62(2):183–187
Elfatairy KK, Filson CP, Sanda MG, Osunkoya AO, Geller RL, Nour SG (2018) In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test–retest reliability study. Br J Radiol 91(1084):20170603
Kaufmann S et al (2018) Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy. World J Urol 36(5):761–768
Steurer S et al (2017) High concordance of findings obtained from transgluteal magnetic resonance imaging-and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. BJU Int 120(3):365–376
Penzkofer T et al (2015) Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology 274(1):170–180
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained from all individual participants included in the study.
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institution and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Institutional ethics committee approval was obtained from Uniting Care Health’s Human Research Ethics Committee for the conduct of this study.
About this article
Cite this article
Pokorny, M., Kua, B., Esler, R. et al. MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. World J Urol 37, 1263–1279 (2019) doi:10.1007/s00345-018-2497-y
- In-bore biopsy
- MRI-guided biopsy
- Multiparametric MRI
- Prostate cancer